Skip to content

US · VVOS · MEDICAL - DEVICES

Vivos Therapeutics, Inc. (VVOS) intrinsic value and stock valuation

$0.05as of 2026-11-21 · Mkt cap 2.01M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Vivos Therapeutics, Inc. DCF and intrinsic value

InvestorsCraft values VVOS with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from VVOS’s statements →

Vivos Therapeutics, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Devices Littleton, CO 80120 vivos.com

How the business is doing

Fiscal 2018–2025, USD

Revenue
$17.4M+5.9% 5y CAGRd
20182025
Net income
-$-21.23M
20182025
Free cash flow
-$-17.6M
20182025
Total equity
-$-1.55M
20182025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2018–2025, USD
20252024202320222021
Revenue$17.4M$15M$13.8M$16M$16.9M
Operating income-$-19.89M-$-11.17M-$-17.3M-$-25.03M-$-19.47M
Net income-$-21.23M-$-11.14M-$-13.58M-$-23.84M-$-20.29M
EPSd-$-2.07M-$-2.22M-$-11.13M-$-25.91M-$-23.87M
Operating cash flow-$-15.26M-$-12.69M-$-11.95M-$-19.59M-$-15.73M
Capital expenditure-$-2.34M-$-570K-$-800K-$-920K-$-2.4M
Free cash flow-$-17.6M-$-13.26M-$-12.75M-$-20.51M-$-18.13M
Total assets$25.2M$15.3M$10.7M$13.7M$33.7M
Total debt$13.5M$1.51M$2M$2.41M$1.63M
Net debt$11.5M-$-4.75M$350K-$-1.11M-$-22.4M
Total equity-$-1.55M$7.95M$410K$4.8M$25.5M
Cash and short-term investments$2.03M$6.26M$1.64M$3.52M$24M
Income statement
20252024202320222021
Revenue$17.4M$15M$13.8M$16M$16.9M
Cost of revenue$6.9M$6.01M$5.53M$6M$4.28M
Gross profit$10.5M$9.02M$8.27M$10M$12.6M
Research and development expenses$0.00$0.00$0.00$0.00$0.00
Selling, general and administrative expenses$29.1M$19.6M$25M$34.4M$31.3M
Other expenses$1.31M$580K$620K$670K$730K
Operating expenses$30.4M$20.2M$25.6M$35.1M$32.1M
Cost and expenses$37.3M$26.2M$31.1M$41.1M$36.4M
Interest income$0.00$0.00$0.00$90K$120K
Interest expense$0.00$0.00$0.00$0.00$10K
Depreciation and amortization$1.31M$580K$620K$670K$730K
Ebitda-$-19.92M-$-10.55M-$-12.96M-$-23.18M-$-19.54M
Operating income-$-19.89M-$-11.17M-$-17.3M-$-25.03M-$-19.47M
Total other income/expenses, net-$-1.34M$40K$3.71M$1.19M-$-820K
Income before tax-$-21.23M-$-11.14M-$-13.58M-$-23.84M-$-20.29M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-21.23M-$-11.14M-$-13.58M-$-23.84M-$-20.29M
Weighted average shares outstanding$10.3M$5.02M$1.22M$920K$850K
Weighted average diluted shares outstanding$10.3M$5.02M$1.22M$920K$850K
Balance sheet
20252024202320222021
Cash and short-term investments$2.03M$6.26M$1.64M$3.52M$24M
Net receivables$1.58M$430K$200K$460K$1.72M
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$4.38M$7.47M$2.46M$5.42M$27.3M
Property, plant and equipment, net$7.92M$4.38M$4.7M$4.78M$2.83M
Goodwill and intangible assets$12.6M$3.21M$3.26M$3.15M$3.18M
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$20.8M$7.81M$8.27M$8.3M$6.37M
Total assets$25.2M$15.3M$10.7M$13.7M$33.7M
Accounts payable$1.68M$1.1M$2.15M$1.41M$920K
Short-term debt$9.08M$480K$470K$420K$1.33M
Deferred revenue$480K$900K$2.14M$2.93M$2.4M
Total current liabilities$18.1M$4.98M$7.29M$6.81M$7.51M
Long-term debt$4.42M$1.03M$1.52M$1.99M$600K
Deferred revenue, non-current$0.00$100K$290K$110K$0.00
Total non-current liabilities$8.63M$2.35M$3.03M$2.11M$640K
Capital lease obligations$4.68M$1.51M$2M$2.41M$370K
Total liabilities$26.7M$7.33M$10.3M$8.92M$8.15M
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings-$-125.36M-$-104.19M-$-93.05M-$-79.47M-$-55.62M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity-$-1.55M$7.95M$410K$4.8M$25.5M
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$13.5M$1.51M$2M$2.41M$1.63M
Net debt$11.5M-$-4.75M$350K-$-1.11M-$-22.4M
Cash flow statement
20252024202320222021
Net income-$-21.23M-$-11.14M-$-13.58M-$-23.84M-$-20.29M
Depreciation and amortization$1.31M$580K$620K$670K$730K
Stock-based compensation$660K$760K$920K$2.4M$2.66M
Change in working capital$4M-$-2.94M$2.86M$1.71M$30K
Accounts receivable-$-220K-$-230K$260K$750K$230K
Inventory$0.00$0.00$0.00$0.00$170K
Accounts payable$520K-$-1.05M$730K$490K$140K
Net cash provided by operating activities-$-15.26M-$-12.69M-$-11.95M-$-19.59M-$-15.73M
Investments in property, plant and equipment-$-2.34M-$-570K-$-850K-$-920K-$-2.4M
Acquisitions, net-$-5.18M$0.00$0.00$0.00-$-230K
Net cash used for investing activities-$-7.53M-$-570K-$-850K-$-920K-$-2.61M
Common stock issued$7.91M$7.8M$10.9M$0.00$25.7M
Common stock repurchased$0.00$0.00$0.00$0.00-$-1.5M
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$18.6M$17.9M$10.9M$0.00$24.2M
Net change in cash-$-4.23M$4.62M-$-1.88M-$-20.51M$5.82M
Cash at end of period$2.03M$6.26M$1.64M$3.52M$24M
Operating cash flow-$-15.26M-$-12.69M-$-11.95M-$-19.59M-$-15.73M
Capital expenditure-$-2.34M-$-570K-$-800K-$-920K-$-2.4M
Free cash flow-$-17.6M-$-13.26M-$-12.75M-$-20.51M-$-18.13M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Vivos Therapeutics, Inc.

        Vivos Therapeutics, Inc. operates as a medical technology company that develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. The company was formerly known as Vivos BioTechnologies, Inc. and changed its name to Vivos Therapeutics, Inc. in March 2018. The company was founded in 2016 and is based in Littleton, Colorado.

        CEO
        R. Kirk Huntsman
        Employees
        268
        Beta
        6.12

        Explore

        Frequently asked questions

        What is the intrinsic value of Vivos Therapeutics, Inc. (VVOS)?

        InvestorsCraft does not currently publish an intrinsic value for VVOS. How the IC value is calculated.

        Is VVOS undervalued?

        InvestorsCraft does not publish an undervaluation signal for VVOS at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.